Research map: A Phase 2, Open-Label, Randomized Controlled Trial Evaluating Safety and Efficacy of Dose-Intensified Versus Standard Dosing Regimens of [ 177 Lu]Lu-PSMA-597 in mCRPC (OPTIMAL-PSMA)

Back to the article

Papers in this map

  1. Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer · Oliver A. Sartor · 2021 · 2844 citations · Cited by this paper
  2. Sub–0.5-mm Resolution PET Versus Autoradiography: Comparison of mGluR1 Concentrations in Mouse Brain · 2026 · Related
  3. [177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study · Michael S. Hofman · 2018 · 1181 citations · Cited by this paper
  4. First-in-Human Imaging Results of PHAROS: A Versatile High-Resolution TOF/DOI PET Scanner for Brain, Breast, and Extremity Imaging · 2026 · Related
  5. [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial · Michael S. Hofman · 2021 · 1159 citations · Cited by this paper
  6. Neuroinflammatory PET in Epilepsy: Prospects for Epileptogenic Zone Localization and Presurgical Planning · 2026 · Related
  7. Dosimetry of 177 Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: Correlations Between Pretherapeutic Imaging and Whole-Body Tumor Dosimetry with Treatment Outcomes · John A. Violet · 2018 · 511 citations · Cited by this paper
  8. Treatment of Human Glioblastoma Multiforme in NRG Mice by Convection-Enhanced Delivery of EGFR-Targeted or Nontargeted Auger Electron–Emitting 197g Hg-Labeled Gold Nanoparticles · 2026 · Related
  9. 177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial · Michael J. Morris · 2024 · 337 citations · Cited by this paper
  10. Preoperative Assessment of Peritoneal Carcinomatosis with [ 68 Ga]Ga-FAPI-46 PET/CT: Agreement with Surgicopathologic PCI and Comparison with MRI and [ 18 F]FDG PET/CT · 2026 · Related
  11. PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial · James Patrick Buteau · 2022 · 292 citations · Cited by this paper
  12. Industry–Academic Collaboration in Nuclear Medicine: Proceedings from the 2024 CMIIT Industry Partners Circle · 2026 · Related
  13. Rapid Modulation of PSMA Expression by Androgen Deprivation: Serial 68 Ga-PSMA-11 PET in Men with Hormone-Sensitive and Castrate-Resistant Prostate Cancer Commencing Androgen Blockade · Louise Emmett · 2018 · 225 citations · Cited by this paper
  14. Translational Theranostics in Glioblastoma: FAPI-46 as a Precision Medicine Tool · 2026 · Related
  15. Prostate-specific membrane antigen cleavage of vitamin B9 stimulates oncogenic signaling through metabotropic glutamate receptors · Charalambos Kaittanis · 2017 · 200 citations · Cited by this paper
  16. [ 18 F]FDG PET/MRI in Pediatric Focal Epilepsies · 2026 · Related
  17. Results of a Prospective Phase 2 Pilot Trial of 177Lu–PSMA-617 Therapy for Metastatic Castration-Resistant Prostate Cancer Including Imaging Predictors of Treatment Response and Patterns of Progression · Louise Emmett · 2018 · 188 citations · Cited by this paper
  18. Radiation-Induced Senescence in Radiopharmaceutical Therapy: Mechanisms and Therapeutic Implications · 2026 · Related
  19. Dosimetry of [177Lu]Lu-PSMA–Targeted Radiopharmaceutical Therapies in Patients with Prostate Cancer: A Comparative Systematic Review and Metaanalysis · Zachary Ells · 2024 · 61 citations · Cited by this paper
  20. Salvage Radiotherapy Confers an Overall Survival Advantage in Biochemical Recurrence of Prostate Cancer: Evidence from the International PROMISE Registry · 2026 · Related
  21. Mechanisms of Resistance to Prostate-Specific Membrane Antigen–Targeted Radioligand Therapy in a Mouse Model of Prostate Cancer · Andreea D. Stuparu · 2020 · 60 citations · Cited by this paper
  22. 177Lu-PSMA-617 and Idronoxil in Men with End-Stage Metastatic Castration-Resistant Prostate Cancer (LuPIN): Patient Outcomes and Predictors of Treatment Response in a Phase I/II Trial · Sarennya Pathmanandavel · 2021 · 59 citations · Cited by this paper
  23. PSMA PET Tumor–to–Salivary Gland Ratio to Predict Response to [ 177 Lu]PSMA Radioligand Therapy: An International Multicenter Retrospective Study · Masatoshi Hotta · 2023 · 56 citations · Cited by this paper
  24. Prostate-Specific Membrane Antigen Expression and Response to DNA Damaging Agents in Prostate Cancer · Beshara Sheehan · 2022 · 52 citations · Cited by this paper
  25. Epigenetic regulation of TP53 is involved in prostate cancer radioresistance and DNA damage response signaling · Catarina Macedo‐Silva · 2023 · 51 citations · Cited by this paper
  26. Prognostic and predictive value of baseline PSMA-PET total tumour volume and SUVmean in metastatic castration-resistant prostate cancer in ENZA-p (ANZUP1901): a substudy from a multicentre, open-label, randomised, phase 2 trial · Louise Emmett · 2025 · 35 citations · Cited by this paper
  27. The Prognostic Value of Posttreatment68Ga-PSMA-11 PET/CT and18F-FDG PET/CT in Metastatic Castration-Resistant Prostate Cancer Treated with177Lu-PSMA-617 and NOX66 in a Phase I/II Trial (LuPIN) · Sarennya Pathmanandavel · 2022 · 34 citations · Cited by this paper
  28. PSMA redirects MAPK to PI3K-AKT signaling to promote prostate cancer progression · Leslie Ann Caromile · 2017 · 31 citations · Cited by this paper
  29. Development of a Visually Calculated SUVmean(HIT Score) on Screening PSMA PET/CT to Predict Treatment Response to177Lu-PSMA Therapy: Comparison with Quantitative SUVmeanand Patient Outcomes · Mina M. Swiha · 2024 · 30 citations · Cited by this paper
  30. Alpha Particle–Emitting Radiopharmaceuticals as Cancer Therapy: Biological Basis, Current Status, and Future Outlook for Therapeutics Discovery · Ryan P. Coll · 2023 · 29 citations · Cited by this paper
  31. 177Lu-DOTA-HYNIC-Lys(Nal)-Urea-Glu: Biokinetics, Dosimetry, and Evaluation in Patients with Advanced Prostate Cancer · Clara Santos‐Cuevas · 2018 · 23 citations · Cited by this paper
  32. DNA Damage in Blood Leukocytes of Prostate Cancer Patients Undergoing PET/CT Examinations with [68Ga]Ga-PSMA I&T · Sarah Schumann · 2020 · 16 citations · Cited by this paper
  33. LBA89 A randomized phase II study of 177Lu-PSMA-617 vs docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC) and PSMA-positive disease: Canadian Cancer Trials Group (CCTG) study PR.21 · K.N. Chi · 2025 · 9 citations · Cited by this paper
  34. Final results of a phase I/II dose-escalation study of fractionated dose 177Lu-PSMA-617 for progressive metastatic castration resistant prostate cancer (mCRPC). · Scott T. Tagawa · 2024 · 7 citations · Cited by this paper

Source: OpenAlex (CC0)